An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus Diet, in Patients With Advanced or Recurrent Endometrial Cancer
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; Serabelisib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Faeth Therapeutics
Most Recent Events
- 13 May 2025 According to Faeth Therapeutics media release, Interim data from this study is anticipated by Q1 of next year, with complete results expected later in 2026.
- 12 Mar 2025 According to Faeth Therapeutics media release, the first patient has been dosed in this trial; David Starks, MD, is Principal Investigator of this trial
- 16 Dec 2024 Status changed from not yet recruiting to recruiting.